Madrigal Pharma (MDGL) Announces Delay in Release of Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- S&P 500 set to open near record highs as Treasury yields cool, oil slips
- Oil slips as Mideast exports, G7 stockpile ease supply concerns
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
| (NASDAQ: MDGL) | Delayed: 493.62 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $493.62 | 52 Week High | $18.24 | |||
| Open | $493.62 | 52 Week Low | $6.60 | |||
| Day High | $493.62 | P/E | N/A | |||
| Day Low | $493.62 | EPS | $0.00 | |||
| Volume | 16 | |||||
